GSK_ Annual_Report_2021-22

161 Notes to the Standalone Financial Statements for the year ended March 31, 2022 PT Smithkline Beecham Pharmaceuticals Ltd., Indonesia PT Glaxo Wellcome Indonesia * no transactions during the year (iv) Directors and members of GSK India Leadership Team : Directors: GSK India Leadership Team: Mr. J. Chandy # (w.e.f. April 1, 2022) Mr. A. Nadkarni Ms. P. Thakur # (upto March 31, 2022) Mr. R. D'souza Mr. S. Venkatesh # (w.e.f. April 1, 2020) Mr. S. Dheri Mr. M. Dawson (w.e.f. Janaury 28, 2021) Ms. S. Choudhary Ms. S.Maheshwari (w.e.f. May 18, 2020) Ms. P. Hingorani Mr. N. Kaviratne Dr. R. Hegde (w.e.f. September 02, 2021) Mr. P. Bhide Mr. R. Manchanda (w.e.f. May 18, 2021) Ms. R. S. Karnad Mr. S. Mitra (w.e.f. April 01, 2021) Mr. A. N. Roy Mr. B. Kotak (upto June 30, 2021) Mr. D. Sundaram Mr. A. Iyer (upto March 31, 2021) Mr. S. Williams Mr. S. Balasubramanian Mr. R. Krishnaswamy # (upto January 27, 2021) Mr. A. Kashyap (w.e.f May 28, 2020) Mr. A. Pandey (w.e.f February 01, 2022) Mr. B. Akshikar (w.e.f December 1, 2020) Mr. C. Sharma (w.e.f December 1, 2020) Mr. N. Hindia (w.e.f January 4, 2021 upto February 28, 2022) Ms. M. Priyam (upto August 31, 2020) Ms. D. Jakate (upto January 31, 2021) Ms. S. Zota (w.e.f March 23, 2020 upto December 31, 2020) Ms. S. Ghosh(w.e.f August 25, 2020 upto December 1, 2020) # Also member of GSK India Leadership Team 2 The following transactions were carried out with the related parties in the ordinary course of business: (i) Dividend paid to parties referred to in item 1(i) above: ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 Glaxo Group Limited, U.K. 164,62.04 219,49.38 GlaxoSmithKline Pte Limited, Singapore 128,53.09 171,37.45 Eskaylab Limited, U.K. 31,75.20 42,33.60 Burroughs Wellcome International Limited, U.K. 18,14.40 24,19.20